Table 3 Treatment and Patient Outcomes
Factor | Total (N = 136) | |
|---|---|---|
n | n (%) | |
Preoperative medical treatment | 134 | 84(62.7) |
• Octreotide | 84 | 68(80.9) |
• Lanreotide | 84 | 6(7.1) |
• Bromocriptine | 84 | 1(1.2) |
• Cabergoline | 84 | 2(2.4) |
• Pegvisomant | 84 | 0 |
• Octreotide + Bromocriptine | 84 | 1(1.2) |
• Octreotide + Cabergoline | 84 | 4(4.8) |
• Octreotide + Pegvisomant | 84 | 2(2.4) |
Transsphenoidal surgery | 136 | 135(99.3) |
Craniotomy required | 132 | 7(5.3) |
Initial complete resection | 135 | 87(64.4) |
Repeat surgery | 136 | 19(14.0) |
Irradiation | 135 | 27(20.0) |
Medication initiated after surgery | 136 | 65(47.8) |
• Somatostatin analog (SSA) | 65 | 32(49.2) |
• Dopamine agonists (DA) | 65 | 3(4.6) |
• Pasireotide | 65 | 0 |
• Pegvisomant (PEG) | 65 | 1(1.5) |
• Combination SSA + DA | 65 | 8(12.3) |
• Combination SSA + PEG | 65 | 7(10.8) |
• Combination DA + PEG | 65 | 2(3.1) |
• Sequential SSA + DA + PEG | 65 | 11(16.9) |
• Sequential SSA + DA + PEG + Pasireotide | 65 | 1(1.5) |
Response to surgery | 87 | 61(70.1) |
Response to medication and/or radiation: | 65 | 31(47.7) |
Hypopituitarism | 133 | 22(16.5) |
Improvement of symptoms after treatment | 118 | 108(91.5) |
Improvement of comorbidities after treatment | 87 | 60(69.0) |